29.
Bennaceur K, Chapman JA, Touraine J-l, Portoukalian J. RETRACTED: immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochi Biophys Acta (BBA)-Rev Cancer. 2009;1795(1):16–24.
31.
Östman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247–74.PubMed
32.
Kammertoens T, Schüler T, Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol Med. 2005;11(5):225–31.PubMed
33.
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.PubMed
34.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.PubMed
35.
Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 2005;17(2):180–6.PubMed
36.
Ramakrishnan S, Subramanian I, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005;8(2):169–82.PubMed
37.
Chechlinska M, Kaminska J, Markowska J, Kramar A, Steffen J. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers. 2006;22(3):172–80.
38.
Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 2007;67(8):3683–90.PubMed
39.
Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996;74(6):1105–15.PubMed
40.
Wong Te Fong L, Gammell S, Bamberger E. Quantification of VEGF-A and PD-ECGF/TP in normal, benign and malignant ovarian lesions. Rev Oncol. 2002;4 suppl 1:122.
41.
Wong Te Fong LF, Kini M, Morris R. Angiogenesis in primary epithelial ovarian carcinomas. Anticancer Res. 2001;21:1662–8.
42.
Fasciani A, D’Ambrogio G, Bocci G, Luisi S, Artini P, Genazzani A. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril. 2001;75(6):1218–21.PubMed
43.
Roszkowski P, Wronkowski Z, Szamborski J, Romejko M. Evaluation of selected prognostic factors in ovarian cancer. Eur J Gynaecol Oncol. 1992;14:140–5.
44.
Zang R, Harter P, Chi D, Sehouli J, Jiang R, Trope C, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105(7):890–6.PubMedCentralPubMed
45.
Ghosh S, Maity P. Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients. Pathol Oncol Res. 2004;10(2):104–8.PubMed
46.
Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, et al. Preoperative serum vascular endothelial growth factor levels significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193–7.PubMed
47.
Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 1998;92(3):360–3.PubMed
48.
Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R, et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res. 2007;13(3):898–901.PubMed
49.
Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005;65(2):465–72.PubMed
50.
Cao R, Björndahl MA, Religa P, Clasper S, Garvin S, Galter D, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004;6(4):333–45.PubMed
51.
Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, et al. Reactive reactive oxygen species regulate epidermal growth factor induced vascular endothelial growth factor and hypoxia-inducible factor-1a expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med. 2006;41:1521–33.PubMed
52.
Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007;6(12):1951–9.PubMed
53.
Liao S, Liu J, Lin P, Shi T, Jain RK, Xu L. TGFbeta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Cancer Res. 2011;17:1415–24.
54.
Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67(2):585–92.PubMedCentralPubMed
55.
Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17(18):6083–96.PubMedCentralPubMed
56.
Yokoyama Y, Xin B, Shigeto T, Mizunuma H. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol. 2011;137(8):1219–28.PubMed
57.
Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, et al. Matrix Metalloproteinases (MMP9 and MMP2) induce the release of Vascular Endothelial Growth Factor (VEGF) by ovarian carcinoma cells implications for ascites formation. Cancer Res. 2003;63(17):5224–9.PubMed
58.
Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003;63(5):906–11.PubMed
59.
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem. 2004;279(6):4339–45.PubMed
60.
Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153(4):1249–56.PubMedCentralPubMed
61.
Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994;54(1):276–80.PubMed
62.
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, et al. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87(7):506–16.PubMed
63.
Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80(1):98–106.PubMed
64.
Sowter H, Corps A, Evans A, Clark D, Charnock-Jones D, Smith S. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest. 1997;77(6):607–14.PubMed
65.
Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer. 1998;83(12):2528–33.PubMed
66.
Zhang L, Yang N, Park J-W, Katsaros D, Fracchioli S, Cao G, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003;63(12):3403–12.PubMed
67.
Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, Volm M. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res. 1996;17(1B):621–4.
68.
Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol. 2004;94(3):630–5.PubMed
69.
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7.PubMedCentralPubMed
70.
Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5(5):355–66.PubMed
71.
Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer. 2012;130(4):857–64.PubMed
72.
Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004;167(2):223–9.PubMedCentralPubMed
73.
Wang J-M, Ko C-Y, Chen L-C, Wang W-L, Chang W-C. Functional role of NF-IL6β and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene. Nucl Acids Res. 2006;34(1):217–31.PubMedCentralPubMed
74.
Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008;6(4):525–34.PubMed
75.
Zhang L, Yang N, Conejo Garcia J-R, Mohamed A, Benencia F, Rubin SC, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002;161(6):2295–309.PubMedCentralPubMed
76.
Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001;97(3):785–91.PubMed
77.
Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Cancer Sci. 1996;87(9):963–71.
78.
Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721–8.PubMed
79.
Pourgholami MH, Cai ZY, Lu Y, Wang L, Morris DL. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res. 2006;12(6):1928–35.PubMed
80.
Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46(11):5629–32.PubMed
81.
Yeo K-T, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993;53(12):2912–8.PubMed
82.
Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998;58(12):2652–60.PubMed
83.
Hampl M, Tanaka T, Albert PS, Lee J, Ferrari N, Fine HA. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum Gene Ther. 2001;12(14):1713–29.PubMed
84.
Stadlmann SAA, Pollheimer J, Gastl G, Offner FA, Margreiter R, et al. Ovarian carcinoma cells and IL1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol. 2005;97:784–9.PubMed
85.
Siddiqui GK, Wong TFL, Rolfe KJ. The expression of VEGF-A in metastatic epithelian ovarian cancer is of prognostic significance. Br J Obstet Gynaecol. 2001;108:549.
86.
Xu L, Fidler IJ. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res Feature Preclin Clin Cancer Therapeut. 2001;12(2):97–106.
87.
Hasumi Y, Mizukami H, Urabe M, Kohno T, Takeuchi K, Kume A, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 2002;62(7):2019–23.PubMed
88.
Liao S, Liu J, Lin P, Shi T, Jain RK, Xu L. TGF-β blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res. 2011;17(6):1415–24.PubMedCentralPubMed
89.
Huang K-J, Sui L-H. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol. 2012;29(1):318–23.PubMed
90.
Nakanishi Y, Kodama J, Yoshinouchi M, Tokumo K, Kamimura S, Okuda H, et al. The expression of vascular endothelial growth factor and transforming growth factor-[beta] associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol. 1997;16(3):256–62.PubMed
91.
Orre M, Rogers PA. VEGF, VEGFR‐1, VEGFR‐2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer. 1999;84(2):101–8.PubMed
92.
Shen G, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000;83(2):196.PubMedCentralPubMed
94.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.PubMed
95.
Lin W-W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–83.PubMedCentralPubMed
96.
Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3(4):276–85.PubMed
97.
Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221–33.PubMed
98.
Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60(1):184–90.PubMed
99.
Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52. Elsevier.PubMed
100.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004;202(1):275–93.PubMed
101.
Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell. 2004;6:297–305.PubMed
103.
Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006;20(6):1130–7.PubMed
104.
Sun JWF, Hsu FC, Bälter K, Zheng SL, Johansson JE, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase 4 and the toll-cell receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:480–5.PubMed
105.
Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002;101:415–22.PubMed
106.
Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998;64(3):275–90.PubMed
107.
Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16(1):35–53.PubMed
108.
Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR. Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene. 2003;23(10):1902–10.
109.
Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13(2):135–41.PubMed
110.
Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor–related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195(2):161–9.PubMedCentralPubMed
111.
Xu J, Zhou J-Y, Wei W-Z, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One. 2010;5(4):e10226.PubMedCentralPubMed
112.
Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22(53):8628–33.PubMed
113.
Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005;2(6):315–24.PubMed
114.
Berger FG. The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat. 2004;88(3):281–5.PubMed
115.
Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000;151(1):31–8.PubMed
116.
Chung YC, Chang YF. Serum interleukin‐6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83(4):222–6.PubMed
117.
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21(4):491–501.
118.
Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002;33(2):213–9.PubMed
119.
Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33(7):708–14.PubMed
120.
Zhang H, Sun X-F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol. 2002;97(4):1037–41.PubMed
121.
Bennaceur K, Chapman JA, Touraine JL, Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta. 2009;1795:16–24.PubMed
122.
Parham C, Chirika M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–708.PubMed
123.
Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 2007;28:207–12.PubMed
124.
Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res. 1999;19(7):697–703.PubMed
125.
Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol. 1997;180(1):55–61.PubMed
126.
Erdman SE, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, et al. Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer. 2010;126(7):1651–65.PubMedCentralPubMed
127.
Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, et al. Ammonium trichloro (dioxoethylene-o, o’) tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 2004;64(5):1843–52.PubMed
128.
Urosevic M, Dummer R. Human leukocyte antigen–G and cancer immunoediting. Cancer Res. 2008;68(3):627–30.PubMed
129.
Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP, et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol. 2000;164(1):436–42.PubMed
130.
Zhang JG, Hepburn L, Cruz G, Borman RA, Clark KL. The role of adenosine A2A and A2B receptors in the regulation of TNF-α production by human monocytes. Biochem Pharmacol. 2005;69(6):883–9.PubMed
131.
Spaner DE. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J Leukoc Biol. 2004;76(2):338–51.PubMed
132.
Moutsopoulos NM, Wen J, Wahl SM. TGF-β and tumors—an ill-fated alliance. Curr Opin Immunol. 2008;20(2):234–40.PubMedCentralPubMed
133.
Seo N, Hayakawa S, Tokura Y. Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol. 2002;12(4):291–300.PubMed
134.
Yu P, Rowley DA, Fu Y-X, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol. 2006;18(2):226–31.PubMed
135.
Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13(4):459–63.PubMed
136.
Mainou-Fowler T, Taylor P, Miller S, Dickinson AM, Proctor SJ. Intracellular cytokine profiles by peripheral blood CD3+ T-cells in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2003;44(8):1325–31.PubMed
137.
Agarwal A, Rani M, Saha G, Valarmathi T, Bahadur S, Mohanti B, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Investig. 2003;32(1–2):17–30.
138.
Dummer W, Bastian BC, Ernst N, Schänzle C, Schwaaf A, Bröcker EB. Interleukin‐10 production in malignant melanoma: Preferential detection of IL‐10‐secreting tumor cells in metastatic lesions. Int J Cancer. 1996;66(5):607–10.PubMed
139.
Becker C, Fantini MC, Neurath MF. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev. 2006;17(1):97–106.PubMed
140.
Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006;177:896–904.PubMed
141.
Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91(17):1459–67.PubMed
142.
Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7):585–97.PubMed
143.
Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer. 1989;60(4):592.PubMedCentralPubMed
144.
Whittmore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136(10):1184–203.
146.
Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol. 1997;145(5):459–65.PubMed
147.
Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 1995;4(5):447–51.
148.
Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women’s Health Study Group. Int J Cancer. 1997;71:948–51.PubMed
149.
Altinoz M, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen-and NSAID-prevention of the ovarian cancer. Neoplasma. 2003;51(4):239–47.
150.
Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction. 2002;123(6):743–50.PubMed
151.
Liu Z, Shimada M, Richards JS. The involvement of the Toll-like receptor family in ovulation. J Assist Reprod Genet. 2008;25(6):223–8.PubMedCentralPubMed
152.
Jabbour HN, Sales KJ, Catalano RD, Norman JE. Focus on vascular function in female reproduction. Inflammatory pathways in female reproductive health and disease. Reproduction. 2009;138:903–19.PubMed
153.
Fleming JS, Beaugié CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol. 2006;247(1):4–21.PubMed
154.
Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71(4):717–21.PubMed
155.
Friedlander M, Dembo A. Prognostic factors in ovarian cancer. Semin Oncol. 1991;18(3):205–12.PubMed
156.
Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176(3):572–9.PubMed
157.
Kyama CM, Debrock S, Mwenda JM, D’Hooghe TM. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol. 2003;1(1):123.PubMedCentralPubMed
158.
Styer AK, Sullivan BT, Puder M, Arsenault D, Petrozza JC, Serikawa T, et al. Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology. 2008;149(2):506–14.PubMedCentralPubMed
159.
Machado DE, Berardo PT, Palmero CY, Nasciutti LE. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. Development. 2010;7:8.
160.
Tariverdian N, Theoharides TC, Siedentopf F, Gutiérrez G, Jeschke U, Rabinovich GA, et al. Neuroendocrine–immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 2007;29(2):193–210.PubMedCentralPubMed
161.
Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42(7):918–31.PubMedCentralPubMed
162.
Demopoulos RI, Aronov R, Mesia A. Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol. 2001;20(2):128–32.PubMed
163.
Cooper MD, Rapp J, Jeffery-Wiseman C, Barnes RC, Stephens DS. Chlamydia trachomatis infection of human fallopian tube organ cultures. J Gen Microbiol. 1990;136(6):1109–15.PubMed
164.
Maisey K, Nardocci G, Imarai M, Cardenas H, Rios M, Croxatto HB, et al. Expression of proinflammatory cytokines and receptors by human fallopian tubes in organ culture following challenge with Neisseria gonorrhoeae. Infect Immun. 2003;71(1):527–32.PubMedCentralPubMed
165.
Strandell A, Thorburn J, Wallin A. The presence of cytokines and growth factors in hydrosalpingeal fluid. J Assist Reprod Genet. 2004;21(7):241–7.PubMedCentralPubMed
167.
Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci. 2012;109(10):3921–6.PubMedCentralPubMed
168.
Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26(6):995–1005.PubMed
169.
Ali‐Fehmi R, Semaan A, Sethi S, Arabi H, Bandyopadhyay S, Hussein YR, et al. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. Cancer. 2011;117(2):301–9.PubMed
170.
Mor G, Yin G, Chefetz I, Yang Y, Alvero A. Ovarian cancer stem cells and inflammation. Cancer Biol Ther. 2011;11(8):708.PubMedCentralPubMed
171.
Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med. 2009;7(1):63.PubMedCentralPubMed
172.
Kelly MG, Alvero AB, Chen R, Silasi D-A, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66(7):3859–68.PubMed
173.
Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58(9):1375–85.PubMed
174.
Muccioli M, Sprague L, Nandigam H, Pate M, Benencia F. Toll-like receptors as novel therapeutic targets for ovarian cancer. ISRN Oncol. 2012;2012:642141.PubMedCentralPubMed
175.
Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, et al. Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 2010;101(4):1059–66.PubMedCentralPubMed
176.
Shan W, Liu J. A hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009;8(19):3107–11.PubMed
177.
Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):e301.PubMedCentral
178.
Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci. 2006;103(44):16472–7.PubMedCentralPubMed
179.
Lane D, Matte I, Rancourt C, Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(1):210.PubMedCentralPubMed
180.
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72(1):66–75.PubMedCentralPubMed
181.
Nash M, Ferrandina G, Gordinier M, Loercher A, Freedman R. The role of cytokines in both the normal and malignant ovary. Endocrinol Relat Cancer. 1999;6(1):93–107.
182.
Asschert JG, Vellenga E, Hollema H, van der Zee AG, de Vries ED. Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumor necrosis factor-alpha (TNFalpha) in p53-characterised human ovarian carcinomas. Eur J Cancer. 1997;33:2246–51.PubMed
183.
Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63(12):3066–8.PubMed
184.
Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103(3):793–6.PubMedCentralPubMed
185.
Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2011;20:799–810. cebp. 1180.2010.
186.
Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett. 2010;31(3):375–83.PubMed
187.
Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomark Prev. 2005;14(4):981–7.
188.
Nowak M, Klink M, Glowacka E, Sulowska Z, Kulig A, Szpakowski M, et al. Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol. 2010;71(2):91–8.PubMed
189.
Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med. 2005;3(1):25.PubMedCentralPubMed
![](https://freepngimg.com/download/social_media/63059-media-icons-telegram-twitter-blog-computer-social.png)
Stay updated, free articles. Join our Telegram channel
![](https://clinicalpub.com/wp-content/uploads/2023/09/256.png)
Full access? Get Clinical Tree
![](https://videdental.com/wp-content/uploads/2023/09/appstore.png)
![](https://videdental.com/wp-content/uploads/2023/09/google-play.png)